Financial Performance - The company's operating revenue for Q1 2023 was ¥101,199,883.45, representing a 10.76% increase compared to ¥91,371,093.42 in the same period last year[5] - Net profit attributable to shareholders decreased by 47.33% to ¥6,584,800.39 from ¥12,501,913.58 year-on-year[5] - Basic and diluted earnings per share both fell by 47.32% to ¥0.0275 from ¥0.0522 in the same period last year[5] - In Q1 2023, the company's net profit was CNY 6,608,510.61, a decrease of 46.9% compared to CNY 12,450,763.04 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 8,275,180.58, down 44.1% from CNY 14,824,181.88 in the same period last year[18] - Total revenue from operating activities was CNY 71,177,372.95, a decline of 8.8% compared to CNY 78,919,381.36 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥71,412,078.80, a decline of 87.61% compared to -¥38,063,764.03 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -71,412,078.80, worsening from CNY -38,063,764.03 in the previous year[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 181,835,488.02, compared to CNY 119,572,132.68 at the end of Q1 2022[20] - The company's cash flow from financing activities increased significantly by 1312.92% to ¥18,670,529.41, primarily due to new bank loans[9] - The company’s financing activities generated a net cash inflow of CNY 18,670,529.41, compared to CNY 1,321,413.90 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,160,864,614.18, a decrease of 0.50% from ¥1,166,753,854.92 at the end of the previous year[5] - Total assets as of March 31, 2023, were ¥1,160,864,614.18, down from ¥1,166,753,854.92 at the beginning of the year, a decrease of 0.5%[16] - Total liabilities decreased to ¥451,762,232.36 from ¥464,259,983.71, a decline of 2.7%[16] - The company's equity attributable to shareholders increased by 0.94% to ¥705,053,220.37 from ¥698,468,419.98 at the end of the previous year[5] Expenses - Total operating costs for Q1 2023 were ¥94,851,970.71, up 21.2% from ¥78,324,425.75 in Q1 2022[17] - The company recorded a net loss from operating activities, with a significant increase in expenses leading to a net profit decline of 46.92%[9] - Research and development expenses increased to CNY 3,035,083.94, up from CNY 2,678,282.04 in the previous year, reflecting a focus on innovation[18] - The company recorded a significant decrease in sales expenses, which rose to CNY 22,923,928.51 from CNY 15,070,557.79, indicating increased investment in marketing[18] - The company's financial expenses included interest expenses of CNY 1,051,034.62, compared to CNY 96,635.60 in the previous year, highlighting increased borrowing costs[18] Receivables and Inventory - The company's receivables financing increased by 60.89% to ¥86,750,573.95, mainly due to an increase in received bills[8] - The company reported a significant increase in accounts receivable financing to ¥86,750,573.95 from ¥53,920,546.58, an increase of 60.9%[15] - Accounts receivable decreased to ¥18,867,109.01 from ¥24,369,559.97, a reduction of 22.6%[15] - Inventory increased to ¥133,364,483.70 from ¥118,222,841.95, reflecting a growth of 12.8%[15] Shareholder Information - The number of major shareholders includes启迪科技服务有限公司 with 70,432,904 shares, representing a significant portion of the company's equity[12]

股票代码：000590 股票简称：启迪药业 启迪药业集团股份公司投资者关系活动记录表 编号：2023-001 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 员姓名 线上参与启迪药业 2022 年度网上业绩说明会的投资者 时间 2023 年 04 月 14 日（星期五）下午 15:00-17:00 地点 "启迪药业投资者关系"微信小程序 上市公司接待人员 姓名 董事、总裁：冯雪先生 董事、副总裁、财务总监：唐婷女士 副总裁、董事会秘书：曹定兴先生 独立董事：龙小明先生 投资者关系活动主 要内容介绍 1、问：请问一下股票价格为什么不高？ 答：尊敬的投资者您好，二级市场的股价表现是多种因 素综合作用的结果。公司将继续努力推动公司高质量发 展，聚焦行业发展，通过创新驱动，品牌驱动，资本驱 动做大做强公司业绩与市值规模，为消费市场提供品质 过硬的品牌产品，为资本市场创造更有投资价值的上市 公司。感谢您对公司的关心和关注。 2、问：古汉养生精在改善老年痴呆等老年退行性疾病 等方面的研究进程？ 答：尊 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-018 参与方式一：在微信小程序中搜索"启迪药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"启迪药业投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：公司董事、总裁冯雪先生，公司副总裁、董 事会秘书曹定兴先生，公司董事、副总裁、财务总监唐婷女士，公司独立董事龙 小明先生。敬请广大投资者积极参与。 启迪药业集团股份公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 启迪药业集团股份公司（以下简称"公司"）已于2023年3月28日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《启迪药业2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年4 月14日（星期五）上午15:00至17:00时在"启迪药业投资者关系"小程序举行2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者 可登陆"启迪药业投资者关系"小程序参与 ...

Financial Performance - The company's operating revenue for 2022 was ¥350,528,110.13, representing a 16.54% increase compared to ¥300,774,612.76 in 2021[23] - The net profit attributable to shareholders decreased by 48.80% to ¥18,145,855.14 from ¥35,438,603.68 in the previous year[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,599,403.81, down 48.10% from ¥22,350,567.85 in 2021[23] - Basic earnings per share decreased by 48.78% to ¥0.0758 from ¥0.1480 in the previous year[23] - The net profit attributable to shareholders for 2022 was approximately ¥698.47 million, representing a 2.67% increase from ¥680.32 million in 2021[24] - The company reported a total revenue of ¥113.98 million in Q4 2022, with a total annual revenue of ¥350.53 million for the year[27] - The net profit attributable to shareholders in Q1 2022 was ¥12.50 million, while Q2 saw a loss of ¥0.95 million, indicating volatility in quarterly performance[27] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 116.20% to ¥54,473,687.13 from ¥25,196,296.92 in 2021[23] - Total assets at the end of 2022 were ¥1,166,753,854.92, a 20.55% increase from ¥967,825,750.64 at the end of 2021[23] - The company achieved operating cash inflow increased by 67.16% to ¥603,348,143.78, driven by higher cash receipts from sales[62] - The net cash flow from operating activities surged by 116.20% to ¥54,473,687.13, indicating improved operational efficiency[62] - As of the end of 2022, cash and cash equivalents amounted to ¥235,421,368.70, representing 20.18% of total assets, a decrease of 5.72% from the beginning of the year[65] Investments and Acquisitions - The company acquired 90% of Qidi Bio for ¥23.5 million to enhance its health product trading business[46] - In August 2022, the company completed the acquisition of 100% of Guangdong Xiantong Pharmaceutical for ¥22 million, aimed at expanding its product line and market competitiveness[46] - The company completed the approval process for two classic formulas, enhancing its product portfolio and market competitiveness[61] - The company has committed to a total investment of 1,000 million yuan for the annual production of 400 million bottles of Gu Han Yang Sheng oral liquid, with 99.99% of the investment completed as of the report date[81] Revenue Sources and Product Performance - The pharmaceutical manufacturing sector accounted for ¥346,525,339.20, or 98.86% of total revenue, with a year-on-year growth of 16.09%[51] - The revenue from traditional Chinese medicine products was ¥295,016,014.20, which is 84.16% of total revenue, showing a growth of 3.56% compared to the previous year[51] - The revenue from direct supply and controlled sales increased by 124.04% year-on-year, reaching ¥74,666,933.4[53] - The company reported a 4.30% increase in revenue for its traditional Chinese medicine subsidiary, but net profit decreased by 34.58% due to rising costs[89] Marketing and Expansion Strategies - The company is enhancing its digital transformation and integrating technology with business operations to drive innovation[44] - The company is focusing on optimizing its marketing structure and expanding its e-commerce presence through platforms like Youzan Mall, Tmall, and JD.com[48] - The company will focus on its core business and expand its market presence nationwide, leveraging the acquisition of Guangdong Xiantong to enhance its terminal sales network and accelerate market expansion[90] - The company plans to strengthen its marketing system and brand management, focusing on key products like "Guhang Yangshengjing" and "Yixin Shupian" to transition from a regional to a national brand[92] Risk Management and Governance - The management has outlined potential risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4] - The company is addressing potential goodwill impairment risks from the acquisition of Guangdong Xiantong by enhancing management and operational efficiency[95] - The company has established a robust governance structure, complying with relevant laws and regulations[98] - The company has not reported any significant differences in governance practices compared to regulatory requirements[98] Employee and Management Structure - The total number of employees at the end of the reporting period is 1,309, with 76 in the parent company and 1,233 in major subsidiaries[129] - The professional composition includes 323 production personnel, 191 sales personnel, 72 technical personnel, 32 financial personnel, 214 administrative personnel, and 477 others[130] - The company has implemented a restricted stock incentive plan for 2022, reflecting its commitment to employee motivation and retention[127] - The current management team includes experienced professionals with diverse backgrounds in finance, law, and pharmaceuticals[111][112][113] Environmental and Social Responsibility - The company operates a wastewater treatment system with a capacity of 1000m³/d, achieving a removal efficiency of 98% for pollutants[146] - The company has implemented a comprehensive quality assurance system for environmental monitoring, adhering to national standards[151] - In 2022, the company invested CNY 30,000 in rural revitalization efforts, establishing sales channels for local specialty agricultural products[155] - The company donated medical supplies valued at over CNY 360,000 to frontline healthcare workers and disease control departments[155] Shareholder and Financial Management - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.7259 million[118] - The company’s total remuneration for the board and management reflects a commitment to competitive compensation practices[117] - The company has not proposed any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[133] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[163]

证券代码：000590 证券简称：启迪药业 公告编号：2022-041 启迪药业集团股份公司 关于参加湖南辖区上市公司2022年投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为贯彻落实《国务院办公厅关于进一步加强资本市场中小投资者合法权益保 护工作的意见》文件精神，进一步做好公司投资者关系管理工作，增强与广大投 资者的沟通交流，切实提高公司透明度和治理水平，启迪药业集团股份公司（以 下简称"公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络 有限公司联合举办的"湖南辖区上市公司 2022年投资者网上集体接待日"活动， 现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司提供的互联网 平台，采用网络远程方式举行，投资者可以登录"全景·路演天下"网站 (http://rs.p5w.net)参与本次投资者网上集体接待日活动，活动时间为：2022 年9月29日（星期四）15:30至 16:55。 届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式与投资 者进行沟通和交流，欢迎广大投资者积 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥178,391,627.39, representing a 20.12% increase compared to ¥148,513,172.63 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 60.43% to ¥11,554,184.55 from ¥29,199,524.56 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was ¥4,995,227.47, down 78.75% from ¥23,506,965.08 in the previous year[17]. - Basic earnings per share decreased by 60.46% to ¥0.0482 from ¥0.1219 year-on-year[17]. - The company's net profit for the first half of 2022 was ¥11,582,235.79, a decrease of 60.3% compared to ¥29,199,524.56 in the same period of 2021[132]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥69,704,048.45, a 159.82% rise compared to the previous year[36]. - The total comprehensive income for the first half of 2022 was ¥11,582,235.79, a significant decrease from ¥29,199,524.56 in the first half of 2021[132]. Cash Flow - The net cash flow from operating activities increased by 40.17% to ¥44,160,594.59, compared to ¥31,504,708.13 in the same period last year[17]. - Cash inflows from operating activities for the first half of 2022 were ¥256,559,891.87, an increase of 34.4% from ¥190,884,978.29 in the first half of 2021[136]. - The net cash flow from investment activities was ¥24,400,626.06, a recovery from a negative cash flow of ¥142,956,896.48 in the previous period[137]. - The total cash flow from financing activities showed a net increase of ¥1,142,827.80, compared to a net outflow of ¥5,062,777.78 in the prior year[137]. - The ending balance of cash and cash equivalents rose to ¥316,065,329.07 from ¥226,437,922.84, reflecting a year-over-year increase of approximately 39.5%[137]. Assets and Liabilities - Total assets at the end of the reporting period were ¥963,489,268.09, a slight decrease of 0.45% from ¥967,825,750.64 at the end of the previous year[17]. - The total liabilities as of June 30, 2022, amounted to CNY 268,085,696.83, down from CNY 285,504,415.17 at the beginning of the year, a decrease of 6.67%[128]. - The company's total equity as of June 30, 2022, was CNY 695,403,571.26, up from CNY 682,321,335.47 at the beginning of the year, an increase of 1.59%[128]. - The total liabilities included accounts payable of ¥29,628,277.33, a decrease from ¥31,544,286.40[123]. Investment and Development - The company has outlined potential risks and countermeasures in its management discussion section, which investors should pay attention to[3]. - The company is focusing on market expansion, channel control, and brand building as part of its marketing strategy to explore new growth opportunities[28]. - The company has completed the registration review for the health food product Dan Shen Hong Hua oral liquid, with the registration certificate expected to be issued soon[31]. - The company has conducted resource surveys and evaluations for 7 types of medicinal materials as part of its classic prescription development project[31]. - The company is committed to the innovation and development of traditional Chinese medicine, focusing on both heritage and modern advancements[31]. - The company plans to enhance its research and development capabilities to drive innovation in its product offerings[152]. Environmental Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period, ensuring compliance with national environmental protection laws and regulations[79]. - The company has implemented a rainwater and sewage diversion project, effectively reducing wastewater generation after investing 900,000 yuan in October 2017[75]. - The company has established an emergency response plan for sudden environmental incidents, focusing on prevention and improving the response mechanism[78]. - The company has conducted environmental self-monitoring according to national standards, with all monitored pollutants meeting or exceeding national discharge standards[79]. Shareholder Information - The total number of shares is 239,471,267, with 99.96% being unrestricted shares[107]. - The number of shareholders at the end of the reporting period is 16,682[109]. - The largest shareholder, Qidi Technology Service Co., Ltd., holds 29.41% of the shares, totaling 70,432,904 shares[109]. - The company has not disclosed any plans for share repurchase or issuance in the current report[107]. Risk Management - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, urging caution regarding investment risks[3]. - The company is actively monitoring raw material prices and implementing cost management strategies to mitigate risks from price fluctuations[65]. - The company plans to enhance its product line by increasing R&D investment and exploring mergers and acquisitions to mitigate risks associated with a single product structure[64].

Financial Performance - The company's revenue for Q1 2022 was ¥92,417,774.85, representing a 20.43% increase compared to ¥76,738,641.22 in the same period last year[2] - Net profit attributable to shareholders decreased by 38.90% to ¥12,501,913.58 from ¥20,462,099.92 year-on-year[2] - Basic and diluted earnings per share fell by 38.88% to ¥0.0522 from ¥0.0854 in the same period last year[2] - The net profit for Q1 2022 was ¥12,450,763.04, a decrease of 39.1% from ¥20,462,099.92 in the same period last year[18] Cash Flow - The net cash flow from operating activities was negative at -¥38,063,764.03, a decline of 1,101.10% compared to ¥3,802,179.07 in the previous year[2] - Cash flow from operating activities showed a net outflow of ¥38,063,764.03, compared to a net inflow of ¥3,802,179.07 in the previous year[20] - The net cash flow from investing activities was -¥90,046,797.81, an increase of 82.64% compared to -¥49,301,913.95 in the previous year, mainly due to increased purchases of financial products[7] - Cash flow from investing activities resulted in a net outflow of ¥90,046,797.81, worsening from a net outflow of ¥49,301,913.95 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥962,747,888.34, a decrease of 0.52% from ¥967,825,750.64 at the end of the previous year[2] - The total liabilities decreased from ¥285,504,415.17 to ¥266,475,789.83, indicating a reduction of approximately 6.7%[14] - Cash and cash equivalents at the end of the period were ¥119,943,241.49, down from ¥250,681,302.32 at the beginning of the year, a decline of 52.2%[12] - The company's inventory decreased from ¥86,592,655.37 to ¥84,374,140.69, a reduction of about 2.5%[12] Shareholder Information - The company has a total of 16,443 common shareholders at the end of the reporting period[9] - The top ten shareholders hold a combined 62.41% of the company's shares, with the largest shareholder owning 29.41%[9] Research and Development - Research and development expenses increased by 46.37% to ¥2,678,282.04, reflecting higher investment in R&D[6] - Research and development expenses increased to ¥2,678,282.04 from ¥1,829,778.17, indicating a focus on innovation[17] Operating Costs - Total operating costs amounted to ¥79,371,107.18, up from ¥60,742,582.21, reflecting a 30.7% increase year-over-year[17] - The company experienced a significant increase in sales expenses, which rose to ¥15,070,557.79 from ¥9,940,230.38, reflecting higher marketing efforts[17] Non-Recurring Gains and Losses - The company reported a total of ¥1,928,696.71 in non-recurring gains and losses for the period[4] Equity - The total equity attributable to the parent company increased from ¥680,322,069.07 to ¥692,823,982.65, reflecting a growth of approximately 1.9%[14]

Financial Performance - The company's operating revenue for 2021 was approximately ¥300.77 million, representing a 9.34% increase compared to ¥275.09 million in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥35.44 million, a significant increase of 55.96% from ¥22.72 million in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥22.35 million, up 20.37% from ¥18.57 million in 2020[21]. - In 2021, the company achieved a total revenue of ¥300,774,612.76, representing a year-on-year growth of 9.34%[39]. - The net profit attributable to shareholders was ¥35,438,603.68, an increase of 55.96% compared to the previous year[39]. - The net profit excluding non-recurring gains and losses was ¥22,350,567.85, reflecting a growth of 20.37% year-on-year[39]. - The company's revenue from the pharmaceutical manufacturing sector was ¥298,486,587.10, accounting for 99.24% of total revenue, with a year-on-year increase of 9.02%[44]. - The total sales revenue for 2021 was approximately ¥298.49 million, with a year-on-year increase of 5.52%[47]. Cash Flow and Assets - The operating cash flow for 2021 was CNY 25,196,296.92, a decrease of 51.06% compared to the previous year[22]. - The total assets increased by 8.48% year-on-year to CNY 967,825,750.64 by the end of 2021[22]. - The net assets attributable to shareholders rose by 5.50% to CNY 680,322,069.07 at the end of 2021[22]. - The net cash flow from operating activities decreased by 51.06% year-on-year, primarily due to increased cash payments for purchased goods[60]. - The total investment during the reporting period was ¥49,349,982.34, representing a 38.28% increase from ¥35,689,240.75 in the same period last year[68]. - The total amount of raised funds used by the company as of December 31, 2021, is RMB 172,458,600.37, including RMB 30,456,400.00 for replacement[79]. - The company reported a net cash outflow from investing activities of ¥115,980,406.16, an increase of 318.32% compared to the previous year's outflow of ¥27,725,143.86[60]. Research and Development - The company is committed to the research and development of traditional Chinese medicine and Western pharmaceutical formulations, aiming to enhance its product offerings and market share[34]. - Research and development expenses decreased by 13.60% to ¥8.29 million, reflecting a strategic shift in resource allocation[55]. - The total research and development (R&D) investment amounted to ¥8,289,522.63, a decrease of 13.60% compared to ¥9,594,178.50 in 2020[60]. - The proportion of R&D investment to operating revenue fell to 2.76%, down from 3.49% in the previous year, a decline of 0.73%[60]. - The R&D budget has increased by 25% this year, totaling 200 million RMB, to support innovation and product development[116]. Market Strategy and Expansion - The company is focusing on expanding its market presence nationally, leveraging its core product, Gu Han Yang Sheng Jing, which has been recognized for its quality and unique formulation[34]. - The pharmaceutical industry is experiencing increased competition and opportunities due to policy reforms and the growth of internet healthcare and pharmaceutical e-commerce[31]. - The company plans to increase investment and expansion efforts in markets outside Hunan Province to mitigate risks associated with product concentration[99]. - Market expansion efforts include entering two new international markets, aiming for a 10% market share within the first year of operation[116]. - The company has completed a strategic acquisition of a smaller biotech firm for 500 million RMB, enhancing its R&D capabilities[116]. Governance and Compliance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations[106]. - The company maintains financial independence with a separate accounting system and does not share bank accounts with its controlling shareholders[111]. - The internal control system has been updated and improved to cover major aspects of the company's operations, with no significant omissions identified[147]. - The company has not identified any significant internal control deficiencies during the reporting period[148]. - The company has fulfilled all commitments made by actual controllers, shareholders, and related parties during the reporting period[169]. Environmental and Social Responsibility - The company has committed to environmental protection laws and has implemented measures to ensure compliance with pollution discharge standards[162]. - The company aims to become "China's first brand in health preservation" and a leading modern pharmaceutical enterprise[164]. - The company has actively engaged in poverty alleviation efforts, providing technical support for a traditional Chinese medicine planting base in Hunan province[166]. - In 2021, the company donated 17,700 yuan to the charity and provided 77,000 yuan in consolation funds to retired workers and model workers[163]. Risks and Challenges - The company acknowledges risks from regulatory changes and market competition, implementing measures to mitigate these risks[94]. - The pharmaceutical industry faces challenges such as increased costs due to rising prices of raw materials and packaging, while drug prices remain stagnant, leading to increased operational pressure[93]. - The main raw materials for production are traditional Chinese medicinal materials, which are subject to price fluctuations due to various factors, potentially impacting profitability[100]. Employee and Management - The total number of employees at the end of the reporting period is 1,214, with 74 in the parent company and 1,140 in major subsidiaries[141]. - The professional composition includes 294 production personnel, 159 sales personnel, and 55 technical personnel[141]. - The company's compensation policy aligns with national regulations, considering external market competitiveness and internal equity[143]. - The performance-based salary structure aims to motivate employees and promote the company's sustainable development goals[143]. - The management team remains stable, with no changes reported in the board of directors or senior management positions during the reporting period[117].

Financial Performance - The company's revenue for Q3 2021 was ¥67,896,908.56, representing a 10.51% increase year-over-year, and a total revenue of ¥216,410,081.19 for the year-to-date, up 22.54% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2021 was ¥9,866,441.56, a significant increase of 79.67%, with year-to-date net profit reaching ¥39,065,966.12, up 102.14% year-over-year[2] - The basic earnings per share for Q3 2021 was ¥0.0412, reflecting a 79.67% increase, while the diluted earnings per share also stood at ¥0.0412, with a year-to-date figure of ¥0.1631, up 102.11%[2] - Total operating revenue for the third quarter of 2021 reached ¥216,410,081.19, an increase of 22.5% compared to ¥176,598,244.43 in the same period last year[16] - The company's net profit for the period was ¥45,285,119.41, compared to ¥22,882,185.11 in the previous year, indicating a significant growth in profitability[16] - The net profit for Q3 2021 was CNY 39,065,966.12, representing a 102.5% increase compared to CNY 19,325,939.31 in the same period last year[18] - Basic earnings per share for Q3 2021 were CNY 0.1631, compared to CNY 0.0807 in the same quarter last year, marking an increase of 102.5%[18] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥920,937,025.61, marking a 3.23% increase from the end of the previous year[2] - Total assets increased to ¥920,937,025.61 from ¥892,157,636.28 at the end of 2020, representing a growth of 3.3%[14] - Total liabilities decreased to ¥236,987,594.10 from ¥247,274,170.89, a reduction of 4.5%[15] - The company's equity attributable to shareholders was ¥644,883,465.39, with retained earnings showing a deficit of ¥114,550,125.76[27] Cash Flow - The company reported a net cash flow from operating activities of ¥29,855,114.23, which is a decrease of 43.39% compared to the previous period[8] - The cash flow from operating activities showed a net inflow of CNY 29,855,114.23, down from CNY 52,736,033.77 in the previous year, reflecting a decrease of about 43.4%[21] - The company reported cash inflows from investment activities totaling CNY 616,535,923.52, significantly higher than CNY 5,800,200.00 in the prior year[22] - The cash outflow for investment activities was CNY 803,091,080.34, compared to CNY 82,307,562.72 in the same period last year, resulting in a net cash outflow of CNY 186,555,156.82[22] - The company reported a decrease in cash flow from financing activities, with a net outflow of CNY 5,062,792.09 compared to a net inflow of CNY 4,911,111.11 in the previous year[22] Inventory and Expenses - The company’s inventory increased by 52.96% to ¥77,736,992.65, primarily due to an increase in raw material reserves[7] - Research and development expenses for the quarter were ¥5,838,340.59, slightly down from ¥6,554,529.71 in the previous year[16] Other Financial Metrics - The company’s weighted average return on equity was 1.45% for Q3 2021, an increase of 0.59% compared to the previous year[2] - The company’s other income increased by 197.58% to ¥6,385,646.71, mainly due to an increase in government subsidies[7] - The company experienced a significant decrease in cash and cash equivalents, down 47.17% to ¥181,190,054.29, primarily due to the purchase of structured deposits[7] - The company reported a decrease in other payables to ¥42,811,263.61 from ¥51,849,591.49, a decline of 17.5%[15] - The company’s retained earnings improved to -¥75,484,159.64 from -¥114,550,125.76, indicating a reduction in accumulated losses[15] Reporting and Transparency - The company has not undergone an audit for the third-quarter report, indicating that the figures are unaudited[28] - The report was released by the board of directors on October 28, 2021, highlighting the company's commitment to transparency[29]

证券代码：000590 证券简称：启迪药业 公告编号：2021-033 启迪药业集团股份公司 关于参加湖南辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为贯彻落实《国务院办公厅关于进一步加强资本市场中小投资者合法权益保 护工作的意见》文件精神，进一步做好公司投资者关系管理工作，增强与广大投 资者的联系和互动交流，切实提高公司透明度和治理水平，启迪药业集团股份公 司（以下简称"公司"）将参加由湖南省证监局主办，湖南省上市公司协会和深 圳市全景网络有限公司协办的"2021年湖南辖区上市公司投资者网上集体接待 日"活动，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司提供的互联网 平台，采用网络远程方式举行，投资者可以登录"全景·路演天下"网站 (http://rs.p5w.net)，参与公司本次投资者网上接待日活动，活动时间为2021 年9月24日(星期五)15:00至17:00。 届时公司董事会秘书、证券事务代表将通过网络在线交流形式与投资者进行 沟通与交流，欢迎广大投资者积极参与。 特此 ...